Oral Antithrombotic Inhibitors: Dabigatran Etexilate, Meeting an Unmet Need?

Clinical and Applied Thrombosis/Hemostasis - United States
doi 10.1177/1076029609344427
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Therapeutic Promise of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor in a Preclinical Model of Colon Carcinogenesis

Clinical and Experimental Pharmacology
2018English

An Unusual Side Effect of Dabigatran Etexilate Use - Acute Renal Failure

Eurasian Journal of Emergency Medicine
2019English

New Options With Dabigatran Etexilate in Anticoagulant Therapy

Vascular Health and Risk Management
2010English

Two and Half Years With Dabigatran Etexilate in Neurological Units

Journal of Vascular Medicine & Surgery
2013English

Triple-Negative Breast Cancer: An Unmet Medical Need

Oncologist
Cancer ResearchMedicineOncology
2011English

An Injectable in Situ Lipid Phase Transition System for Sustained Delivery of Dabigatran Etexilate With Low Burst Release

RSC Advances
ChemistryChemical Engineering
2017English

Unmet Need: Specific Pcos-Diagnostic

International Journal of Family & Community Medicine
2018English

Dabigatran Etexilate Activation Is Affected by the CES1 Genetic Polymorphism G143E (Rs71647871) and Gender

Biochemical Pharmacology
BiochemistryPharmacology
2016English

The Analyses of Patients Whose APTT Were Prolonged by the Administration of Dabigatran Etexilate

Nosotchu
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy